Moderna (MRNA) said Friday it has completed the construction of a research and production facility in Japan but will not proceed with a separate plan to build an mRNA drug substance manufacturing site.
The completed facility, led by Moderna Enzymatics, is located at Shonan Health Innovation Park in Kanagawa Prefecture in Japan and is focused on mRNA research and manufacturing using cell-free DNA synthesis technology, the company said.
Moderna cited evolving global and domestic conditions as the reason for canceling the separate manufacturing site but said it may revisit the project in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.